Volume | 2,393,636 |
|
|||||
News | - | ||||||
Day High | 12.0157 | Low High |
|||||
Day Low | 11.65 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.96 | 11.65 | 12.0157 | 11.70 | 12.05 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
19,525 | 2,393,636 | $ 11.77 | $ 28,162,992 | - | 9.475 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:40:20 | 5 | $ 11.75 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.53B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.08 | 13.26 | 11.65 | 12.21 | 3,206,629 | -1.32 | -10.09% |
1 Month | 12.35 | 13.265 | 11.65 | 12.55 | 2,247,607 | -0.59 | -4.78% |
3 Months | 13.97 | 15.01 | 11.65 | 13.21 | 2,024,780 | -2.21 | -15.82% |
6 Months | 13.70 | 15.15 | 11.65 | 13.55 | 1,787,138 | -1.94 | -14.16% |
1 Year | 9.52 | 15.15 | 9.475 | 13.18 | 1,651,625 | 2.24 | 23.53% |
3 Years | 10.03 | 21.39 | 7.09 | 12.86 | 2,217,834 | 1.73 | 17.25% |
5 Years | 7.97 | 21.39 | 1.80 | 9.76 | 2,600,259 | 3.79 | 47.55% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |